EWTX Q4 2025 Earnings — Edgewise Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

EWTXEdgewise Therapeutics, Inc.

$3B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$56M

Net Income

-$50M

EPS (Diluted)

$-0.47

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$38M

Stock-Based Comp.

-$25M

Balance Sheet

Total Assets

$553M

Total Liabilities

$30M

Stockholders' Equity

$522M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$56M	-$46M	-22.9%
Net Income	-$50M	-$40M	-26.6%